Wells Fargo & Company Cardiol Therapeutics Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CRDL
# of Institutions
45Shares Held
5.47MCall Options Held
162KPut Options Held
7.4K-
Tejara Capital LTD London, X01.72MShares$3.29 Million1.26% of portfolio
-
Advisor Shares Investments LLC Bethesda, MD1.47MShares$2.8 Million0.55% of portfolio
-
Mmcap International Inc. Spc Grand Cayman, E9924KShares$1.77 Million0.36% of portfolio
-
Lion Street Advisors, LLC253KShares$483,7660.19% of portfolio
-
Cambridge Investment Research Advisors, Inc.116KShares$221,8100.0% of portfolio
About Cardiol Therapeutics Inc.
- Ticker CRDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 61,942,500
- Market Cap $118M
- Description
- Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...